{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:11Z","timestamp":1761920471902},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Am Assoc Nurse Pract"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and purpose:<\/jats:title>\n            <jats:p>Despite demonstrated efficacy, the utilization of herpes zoster vaccine (HZV), recommended by the Centers for Disease Control (CDC) for all immunocompetent adults aged above 60 years, is low (31%). The aim of this study was to identify nurse practitioner (NP) barriers to HZV administration and then to use these results to develop and evaluate the outcomes of an educational program.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study used a two-phase design. In Phase I, barriers that obstruct the provision of HZV were identified and NPs were surveyed to determine current HZV practice. The second phase used a quasiexperimental pretest\u2013posttest design to evaluate the impact of the constructed program.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In Phase I, NYS Primary Care NPs with practice years ranging from 1 to 24, who reported working in practice sites that ranged from 1 to 20 providers, possessed limited knowledge of the vaccine, especially, the financial aspects of the vaccination such as up-front cost (46%), cost to patients (39%), and reimbursement (29%), resulting in fewer provider recommendations. In Phase II, a paired-samples <jats:italic toggle=\"yes\">t<\/jats:italic> test revealed a statistically significant difference between pretest scores (mean = 3.4, SD = 1.2) and posttest scores (mean = 4.7, SD = 1.3) on the knowledge survey, t (37) = \u22127.1, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .0, demonstrating NPs' improved understanding of HZV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Implications for practice:<\/jats:title>\n            <jats:p>Nurse practitioners will increase compliance with the CDC recommendations for HZV administration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/jxx.0000000000000039","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T22:08:27Z","timestamp":1529014107000},"page":"435-440","source":"Crossref","is-referenced-by-count":3,"title":["Improving herpes zoster vaccine rates: The impact of a targeted educational program"],"prefix":"10.1097","volume":"30","author":[{"given":"Margaret","family":"O'Donnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Shurpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Janotha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230821","doi-asserted-by":"crossref","first-page":"D114","DOI":"10.1016\/j.vaccine.2015.09.054","article-title":"Meeting the challenges of immunizing adults","volume":"33","author":"Bridges","year":"2015","journal-title":"Vaccine"},{"key":"R2-20230821","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1370\/afm.1185","article-title":"Vaccines provided by family physicians","volume":"8","author":"Campos-Outcalt","year":"2010","journal-title":"Annals of Family Medicine"},{"key":"R4-20230821","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Eng J Med"},{"key":"R5-20230821","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/14712598.2013.830101","article-title":"Zostavax: A subcutaneous vaccine for the prevention of herpes zoster","volume":"13","author":"Doan","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"R7-20230821","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/ICO.0b013e318283453a","article-title":"Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination","volume":"32","author":"Elkin","year":"2013","journal-title":"Cornea"},{"key":"R8-20230821","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.vaccine.2010.12.097","article-title":"Primary care physician perspectives on providing adult vaccines","volume":"29","author":"Freed","year":"2011","journal-title":"Vaccine"},{"key":"R9-20230821","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.2105\/AJPH.2012.300665","article-title":"Improving adult immunization practices using a team approach in the primary care setting","volume":"102","author":"Gannon","year":"2012","journal-title":"Am J Public Health"},{"key":"R10-20230821","first-page":"729","article-title":"Update on recommendations for use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R11-20230821","first-page":"1","article-title":"Prevention of herpes zoster: Recommendations of the advisory committee on immunization practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"R12-20230821","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/003335491613100216","article-title":"Physician attitudes toward adult vaccines and other preventive practices, United States, 2012","volume":"131","author":"Hurley","year":"2016","journal-title":"Public Health Reports"},{"key":"R13-20230821","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M13-2332","article-title":"U.S. Physicians' perspective of adult vaccine delivery","volume":"160","author":"Hurley","year":"2014","journal-title":"Ann Intern Med"},{"key":"R14-20230821","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1086\/522153","article-title":"National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine","volume":"197","author":"Hurley","year":"2008","journal-title":"J Infect Dis"},{"key":"R15-20230821","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7326\/0003-4819-152-9-201005040-00005","article-title":"Barriers to the use of herpes zoster vaccine","volume":"152","author":"Hurley","year":"2010","journal-title":"Ann Intern Med"},{"key":"R27-20230821","doi-asserted-by":"crossref","DOI":"10.1177\/1060028018758431","article-title":"Shingrix: The new adjuvanted recombinant herpes zoster vaccine","author":"James","year":"2018","journal-title":"Ann Pharmacother"},{"key":"R17-20230821","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2008.05.005","article-title":"Barriers to adult immunization","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"key":"R18-20230821","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BioMed Central Infectious Diseases"},{"key":"R19-20230821","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Intern Med"},{"key":"R20-20230821","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ppar\/22.4.20","article-title":"The continuing challenge of adult Immunizations: Impact of the affordable care act","volume":"22","author":"Tan","year":"2012","journal-title":"Public Policy & Aging Report"},{"key":"R21-20230821","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1016\/j.vaccine.2014.08.040","article-title":"Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies","volume":"32","author":"Teeter","year":"2014","journal-title":"Vaccine"},{"key":"R24-20230821","first-page":"492","article-title":"Immunization in the United States: Recommendations, barriers, and measures to improve compliance: Part 2: Adult vaccinations","volume":"41","author":"Ventola","year":"2016","journal-title":"Pharmacy and Therapeutics"},{"key":"R25-20230821","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/2327-6924.12459","article-title":"Comparison of immunization rates of adults ages 65 years and older managed within two nurse practitioner\u2013owned clinics with national immunization rates","volume":"29","author":"Wright","year":"2017","journal-title":"J Am Ass Nurse Pract"},{"key":"R26-20230821","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01741002-201808000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T09:06:29Z","timestamp":1692608789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201808000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/jxx.0000000000000039","relation":{},"ISSN":["2327-6924"],"issn-type":[{"value":"2327-6924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}